Skip to content
10-Q

Quarterly Report

Deciphera Pharmaceuticals, Inc.

0001654151-24-000018

← back to feed
Filed
May 10, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 6, 2024 86.48M sh
Shares Diluted Q1 2024 · Mar 31, 2024 87.39M sh
Shares Diluted Q1 2024 · Mar 31, 2023 82.68M sh
Capex Q1 2024 · Mar 31, 2024 $146K
Capex Q1 2024 · Mar 31, 2023 $360K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$54.59M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$49.46M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $91.23M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $83.51M
Stockholders Equity Q1 2024 · Mar 31, 2024 $316.05M
Stockholders Equity Q1 2024 · Dec 31, 2023 $350.92M
Stockholders Equity Q1 2024 · Mar 31, 2023 $440.08M
Stockholders Equity Q1 2024 · Dec 31, 2022 $341.69M
Current Liabilities Q1 2024 · Mar 31, 2024 $83.43M
Current Liabilities Q1 2024 · Dec 31, 2023 $100.28M
Total Liabilities Q1 2024 · Mar 31, 2024 $104.88M
Total Liabilities Q1 2024 · Dec 31, 2023 $122.65M
Current Assets Q1 2024 · Mar 31, 2024 $349.94M
Current Assets Q1 2024 · Dec 31, 2023 $381.1M
Total Assets Q1 2024 · Mar 31, 2024 $420.93M
Total Assets Q1 2024 · Dec 31, 2023 $473.57M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.52
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.60
Eps Basic Q1 2024 · Mar 31, 2024 −$0.52
Eps Basic Q1 2024 · Mar 31, 2023 −$0.60
Sga Expense Q1 2024 · Mar 31, 2024 $33.92M
Sga Expense Q1 2024 · Mar 31, 2023 $31.45M
Rd Expense Q1 2024 · Mar 31, 2024 $57.83M
Rd Expense Q1 2024 · Mar 31, 2023 $54.77M
Net Income Q1 2024 · Mar 31, 2024 −$45.08M
Net Income Q1 2024 · Dec 31, 2023 −$194.9M
Net Income Q1 2024 · Mar 31, 2023 −$49.61M
Operating Income Q1 2024 · Mar 31, 2024 −$48.85M
Operating Income Q1 2024 · Mar 31, 2023 −$53.26M
Cost Of Revenue Q1 2024 · Mar 31, 2024 $2.09M
Cost Of Revenue Q1 2024 · Mar 31, 2023 $488K
Revenue Q1 2024 · Mar 31, 2024 $45M
Revenue Q1 2024 · Mar 31, 2023 $33.45M